mRNA influenza vaccine

Clinical Trial of mRNA Universal Influenza Vaccine Candidate Begins Clinical trial, experimental universal influenza vaccine National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC), (part of National Institutes of Health) Enrolling volunteers, Duke University, Durham, North Carolina Phase 1 trial H1ssF-3928 mRNA-LNP, for safety and ability to induce an immune response. N = up to 50 healthy volunteers, (18 through 49) Three groups of 10 participants each 10, 25 and 50 micrograms After evaluation of the data to determine an optimum dosage, an additional 10 to receive the optimum dosage Study include a group, receive a current quadrivalent. Comparison between “immunogenicity and safety” Follow-up appointments for up